drugset / Trial / NCT01150123

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women

NCT01150123 ↗

Phase 1 Completed 678 enrolled Novartis Vaccines GlaxoSmithKline · collab
RandomizedParallel-groupSingle-blindPrevention

Summary

This study will evaluate the safety and immunogenicity of a Group B Streptococcus vaccine.

Timeline

Start
2010-05
Primary completion
2011-11
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Group B streptococcus (GBS) vaccine Vaccine 5 ug —
Subject Group B streptococcus (GBS) vaccine Vaccine 20 ug —